158 related articles for article (PubMed ID: 2670515)
1. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.
Brogden RN; Clissold SP
Drugs; 1989 Aug; 38(2):185-203. PubMed ID: 2670515
[TBL] [Abstract][Full Text] [Related]
2. Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer.
Brogden RN; Chrisp P
Drugs Aging; 1991 Mar; 1(2):104-15. PubMed ID: 1794008
[TBL] [Abstract][Full Text] [Related]
3. Flutamide: an antiandrogen for advanced prostate cancer.
Goldspiel BR; Kohler DR
DICP; 1990 Jun; 24(6):616-23. PubMed ID: 2193461
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
5. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
Lacoste D; Dubé D; Bélanger A; Labrie F
Mol Cell Endocrinol; 1989 Dec; 67(2-3):131-8. PubMed ID: 2693158
[TBL] [Abstract][Full Text] [Related]
6. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Belanger A; Lachance R; Emond J; Monfette G
J Steroid Biochem; 1987; 27(1-3):525-32. PubMed ID: 2961937
[TBL] [Abstract][Full Text] [Related]
8. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
9. Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma.
Sogani PC; Whitmore WF
Cancer Treat Res; 1988; 39():131-45. PubMed ID: 2908604
[TBL] [Abstract][Full Text] [Related]
10. Benefits of combination therapy with flutamide in patients relapsing after castration.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Lacourciere Y; Monfette G; Emond J; Bergeron N
Br J Urol; 1988 Apr; 61(4):341-6. PubMed ID: 3289676
[TBL] [Abstract][Full Text] [Related]
11. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment versus LHRH alone in advanced prostatic cancer.
Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
[TBL] [Abstract][Full Text] [Related]
13. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G; Kolvenbag G; Nash A
Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
[TBL] [Abstract][Full Text] [Related]
14. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Benson R; Dorr FA; Blumenstein BA; Davis MA; Goodman PJ
N Engl J Med; 1989 Aug; 321(7):419-24. PubMed ID: 2503724
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Raina R; Pahalajani G; Agarwal A; Zippe C
Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
[TBL] [Abstract][Full Text] [Related]
16. [Suppressive effects of the antiandrogen flutamide on adrenal androgens in advanced prostate cancer patients].
Nakazato H; Suzuki K; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):6-12. PubMed ID: 11235144
[TBL] [Abstract][Full Text] [Related]
17. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.
Brogden RN; Faulds D
Drugs Aging; 1995 Apr; 6(4):324-43. PubMed ID: 7613021
[TBL] [Abstract][Full Text] [Related]
18. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
19. Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study.
Lund F; Rasmussen F
Br J Urol; 1988 Feb; 61(2):140-2. PubMed ID: 3280080
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]